MMM — Medicare/Medicaid
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. Pricing proposals such as reference pricing/Most Favored Nations as they relate to access to plasma derived therapies.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS)
TRD — Trade (domestic/foreign)
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)